Product Description
Viteyes AREDS 2 Softgels are based on the clinically effective formula tested by the National Eye Institute ("NEI") in its 2013 AREDS2 study. This formula is found in 2 easy-to-swallow softgels daily. Viteyes AREDS 2 is also available in its original capsule form. Completed in 2013, AREDS 2 was a 5-year nationwide study sponsored by the National Eye Institute (NEI). The AREDS 2 study was a follow up on the original AREDS study. AREDS 2 resulted in the NEI's recommendation to revise the original AREDS formula to help further slow the progression of vision loss from AMD.* Viteyes® AREDS 2 is based on these findings and contains the following formula in 2 softgels daily: Vitamin C - 500 mg, Vitamin E - 400 IU, Zinc - 25 mg - Lower Zinc!, Copper - 1.2 mg, Lutein - 10 mg, Zeaxanthin - 2 mg. AREDS 2 analyzed the original AREDS formula from NEI's 2001 recommendation with and without beta-carotene. This was due to the concern of an increased risk of lung cancer for smokers and former smokers taking high doses of beta-carotene. The AREDS 2 study also researched adding lutein and zeaxanthin. AREDS 2 participants who took lutein and zeaxanthin and no beta-carotene reduced their risk of developing advanced stages of AMD by 18% compared to those in AREDS 2 who took the original AREDS supplement with beta-carotene. As a result, the NEI's AREDS 2 suggests modifying the AREDS formula by omitting beta-carotene and adding lutein and zeaxanthin. Zinc Levels: "In the original AREDS study, the dose for zinc was set high (80 mg) because a previous small trial had found that high-dose zinc was beneficial for AMD. However, some nutritionists were concerned the dose was too high."* The AREDS 2 study tested zinc at 80 mg and 25 mg. The results showed that when lowering zinc there was "no statistically significant effect on progression to advanced AMD."Feature
Viteyes AREDS 2 Softgels are based on the clinically effective formula tested by the National Eye Institute (NEI") in its 2013 AREDS2 study